Details of the Drug

General Information of Drug (ID: DMUWBIJ)

Drug Name
Propiverine
Synonyms
propiverine hydrochloride; 54556-98-8; Propiverine HCl; Mictonorm; Propiverine Hydrochlorride; UNII-DC4GZD10H3; (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride; DSSTox_RID_81957; DSSTox_CID_26847; DSSTox_GSID_46847; C23H29NO3.HCl; DC4GZD10H3; CAS-54556-98-8; NCGC00181103-01; Mictonetten; Pollarine; Mictonorm (TN); propiverin hydrochloride; Bup-4 (TN); AC1L9B4A; CHEBI:8494; SCHEMBL1034248; DTXSID1046847; CHEMBL2359059; Propiverine hydrochloride (JP17); KFUJMHHNLGCTIJ-UHFFFAOYSA-N; BCP09576; Tox21_112719; NSC172140
Indication
Disease Entry ICD 11 Status REF
Urinary incontinence MF50.2 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 367.5
Logarithm of the Partition Coefficient (xlogp) 4.7
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 16 mcgh/L [2]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 8.2 mcg/L [2]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1 h [2]
Bioavailability
The bioavailability of drug is 6% [2]
Clearance
The total clearance of drug is 371 mL/min [3]
Elimination
60% radioactivity was recovered in urine and 21% was recovered in feces within 12 days, and less than 1% of an oral dose is excreted unchanged in the urine [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 22.1 hours [3]
Metabolism
The drug is metabolized via the liver [4]
Unbound Fraction
The unbound fraction of drug in plasma is 0.1% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.73 L/kg [5]
Chemical Identifiers
Formula
C23H29NO3
IUPAC Name
(1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate
Canonical SMILES
CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C
InChI
InChI=1S/C23H29NO3/c1-3-18-26-23(19-10-6-4-7-11-19,20-12-8-5-9-13-20)22(25)27-21-14-16-24(2)17-15-21/h4-13,21H,3,14-18H2,1-2H3
InChIKey
QPCVHQBVMYCJOM-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4942
ChEBI ID
CHEBI:8493
CAS Number
60569-19-9
DrugBank ID
DB12278
TTD ID
D0TV9K
INTEDE ID
DR1363
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Muscarinic acetylcholine receptor M5 (CHRM5) TTH18TF ACM5_HUMAN Antagonist [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Ditropan XL FDA label
3 Mictoryl monograph
4 Pharmacokinetic Studies on Propiverine Hydrochloride
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland. Life Sci. 1999;64(25):2351-8.
7 Product monograph: Mictoryl (Propiverine hydrochloride modified-release capsules).